This Action will bring together chronic GvHD (cGvHD) researchers across Europe for the first time, creating a network of cross-disciplinary experts in the field.
We aim to link research groups, clinical teams and industry partners throughout Europe to enable a breakthrough in scientific developments, leading to new concepts for improving the survival and quality of life of transplant patients.
The Action will lead to an improved understanding of the pathogenesis of cGvHD and its associated co-morbidities, and will develop a coordinated approach to therapy, strengthening European research and innovation via collaboration.
What is the project about?
Chronic GvHD (cGvHD) is a multi-organ allo and autoimmune disorder and a major cause of non-relapse morbidity and mortality following allogeneic haematopoietic stem cell transplantation (HSCT).
It occurs in an estimated 50% of patients per year worldwide and causes a plethora of co-morbidities. There is a lack of coordination at the European research level into cGVHD diagnosis and therapy and this impacts on patient care, due to a non-uniform treatment approach across transplant centres.
Chronic GvHD (cGvHD) is a multi-organ allo and auto immune disorder and a major cause of non-relapse morbidity and mortality following allogeneic haematopoietic stem cell transplantation (HSCT).
Chronic GvHD (cGvHD) occurs in an estimated 50% of patients per year worldwide and causes a plethora of co-morbidities.
This COST Action will serve as a platform for industry, clinical teams and researchers from cross-disciplines, including bioinformatics, immunology, epidemiology, genetics and cell biology, to enable the dissemination of integrated clinical and laboratory information via established and improved databases.
The COST Action will promote novel research as well as more uniform treatment of the disease. Innovation will be accelerated by coordination, networking and introduction of new technologies and therapies for the benefit of patients by being able to more accurately predict and treat the disease and its co-morbidities.
Early career investigators (ECI’s) will learn how genomics, proteomics and immunology interact to provide a more personalised medicine approach to treat disease and improve patient outcomes. By studying large-scale populations and coming together as a network, we will further understand the pathogenesis of cGvHD, its subsets and associated comorbidities and develop a coordinated approach to therapy.
By studying large-scale populations, the Action will enable us to understand the pathogenesis of cGvHD and develop a coordinated approach to therapy.
Do you have a question?
If you have any questions or would like to know more about the project, simply connect with us and we’ll be happy to talk to you.